Mochi Health vs TrimRx: Flat-Rate Pricing With Pharmacy Enforcement vs Top-Rated Specialist
Mochi Health and TrimRx are different shapes of compounded-GLP-1 specialist serving overlapping audiences. Mochi competes on flat-rate pricing ($99/month semaglutide and $199/month tirzepatide at every dose tier) and a strong consumer-experience signal (Trustpilot 4.4/5 across 15,600+ reviews). TrimRx competes on accreditation depth: LegitScript-certified at the platform level, BBB-accredited B, partner pharmacies that are themselves LegitScript-certified, no FDA enforcement, no manufacturer lawsuits, no state pharmacy enforcement. The choice usually comes down to whether Mochi's pricing innovation outweighs the substantiated pharmacy-quality concerns at its affiliated compounding pharmacy.
Mochi Health
2.8Flat-rate compounded GLP-1 with a vertically-integrated pharmacy under active state and federal scrutiny
TrimRx
4.3LegitScript-certified compounded GLP-1 telehealth
Reviewed by Designing Longevity Editorial·Last verified May 1, 2026
Bottom line
TrimRx for almost every reader. The pricing gap is real but small once you account for what each provider actually costs at typical dose tiers, and the trust-signal gap is unusually wide because Mochi's affiliated compounding pharmacy Aequita received a Washington State Notice of Immediate Jeopardy after substantiated whistleblower allegations of unlicensed-worker sterile compounding and improper cold-chain shipping. Choose Mochi only if flat-rate dose-independent pricing is specifically what you want, you have read the WA State enforcement record, and you've decided you're comfortable with it.
Side-by-side at a glance
Who wins for each use case
We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.
Pharmacy-quality regulatory record
Winner: TrimRxTrimRx has no FDA enforcement actions, no state pharmacy enforcement, and partner pharmacies that are LegitScript-certified. Mochi's affiliated compounding pharmacy Aequita received a WA State Limited Stop Service that escalated to a Notice of Immediate Jeopardy after substantiated whistleblower allegations of unlicensed sterile compounding and improper cold-chain shipping. This is the most material trust-signal gap in any of our compounded-GLP-1 head-to-heads.
Manufacturer lawsuit posture
Winner: TrimRxMochi has two active federal lawsuits: Eli Lilly v. Mochi Health (April 2025, marketing) and Novo Nordisk v. Mochi Health Corp. 5:25-cv-06563 (August 2025, marketing plus corporate-practice-of-medicine). TrimRx has no comparable open manufacturer litigation. The Novo case adds a structural claim that goes beyond marketing language; if it succeeds it would constrain how Mochi structures prescribing relationships.
Accreditation stack
Winner: TrimRxTrimRx has the strongest accreditation stack in our compounded cohort: LegitScript Healthcare Merchant Certification at the platform level, BBB-accredited with a B rating, and partner pharmacies that are themselves LegitScript-certified. Mochi is NOT BBB-accredited; LegitScript certification is claimed by Mochi materials but not independently confirmable on a public registry; Aequita's accreditation status is not publicly surfaced.
External review platform signal
Winner: Mochi HealthMochi has 4.4/5 across 15,600+ Trustpilot reviews with no fraud notice, the largest external review sample in our compounded-GLP-1 cohort. TrimRx has BBB-accredited B but a smaller external review sample. The volume gap is real and Mochi wins this row, with the caveat that the consumer-experience signal at Mochi is happening at a pharmacy with documented operational issues; many users may not have encountered the issues that drove the WA enforcement.
Flat-rate dose-independent pricing
Winner: Mochi HealthMochi charges $99/month for compounded semaglutide and $199/month for compounded tirzepatide at every dose tier including the maximum therapeutic dose. TrimRx pricing escalates with dose at typical cohort rates. For users who titrate up to higher doses, Mochi wins on titration economics; for users staying at lower doses, the pricing gap is smaller.
Cash-pay all-in cost
Winner: Mochi HealthMochi's all-in cost lands roughly $178/month for semaglutide ($79 membership + $99 medication, flat across all doses) and $278/month for tirzepatide ($79 + $199). TrimRx's all-inclusive cash-pay program starts at $179/month for semaglutide and $259/month for tirzepatide at lower doses, with escalation at higher doses. Mochi wins on the dose-independent math; the pricing innovation is a real differentiator.
Per-fill sourcing transparency
Winner: TrimRxTrimRx names LegitScript-certified partner pharmacies with the certification stack documented at the partner level. Mochi's vertical-integration story (Aequita ownership) was used as a quality differentiator in marketing while the substantiated whistleblower allegations against Aequita are now public record. Vertical integration that contradicts the marketing is worse than partner-pharmacy disclosure that holds up under scrutiny.
Operational maturity
Winner: TrimRxBoth are relatively young companies in this category. TrimRx has steadily accumulated accreditations and clean regulatory record; Mochi has accumulated lawsuits and state pharmacy enforcement against its affiliated pharmacy. Trajectory matters: TrimRx is growing into a more credible operator over time, Mochi is fighting a multi-front regulatory battle.
Rubric scores side-by-side
Same six dimensions we use on every provider profile, weighted to a single 0-5 score. Click through to either profile for the verification details behind each row.
Licensure 20% weight
Accreditation 20% weight
Transparency 20% weight
Product quality 15% weight
Pricing 15% weight
Customer service 10% weight
Pricing in plain terms
Mochi: $79/mo membership + $99/mo flat semaglutide or $199/mo flat tirzepatide at every dose ($178-$278/mo all-in). TrimRx: all-inclusive cash-pay starting at $179/mo semaglutide or $259/mo tirzepatide with dose-tier escalation. The pricing gap favors Mochi on max-dose protocols (where the dose-independence pays off) and is roughly comparable at lower doses. The trust-signal gap favors TrimRx by a much wider margin than the pricing gap. For most readers, the trust premium is worth paying.
Read the full profiles
This comparison summarizes the head-to-head call. The full provider profiles include verification items, regulatory history, public-review aggregation, and the signup walkthrough.